ClinicalTrials.Veeva

Menu

The Effect of Closed-Loop Versus Conventional Ventilation on Mechanical Power (INTELLiPOWER)

A

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Status

Completed

Conditions

Mechanical Ventilation
Mechanical Power

Treatments

Procedure: Procedure: Conventional ventilation
Procedure: Procedure: INTELLiVENT-ASV

Study type

Interventional

Funder types

Other

Identifiers

NCT04827927
INTELLiPOWER

Details and patient eligibility

About

Several studies suggest fully-automated ventilation to ventilate with a lower amount of MP in unselected ICU patients, patients after cardiac surgery, and patients with and without ARDS. The current study will directly compare the amount of MP in invasively ventilated critically ill patients by calculating MP breath-by-breath, using the various equations proposed in the literature.

Full description

Rationale:

Mechanical ventilation can cause ventilator-induced lung injury (VILI). Lung protective ventilation, consisting of a low tidal volume (VT), a low plateau pressure (Pplateau) and a low driving pressure (ΔP) improves survival and shortens duration of ventilation in patients with acute respiratory distress syndrome (ARDS). Lung protective ventilation may also benefit critically ill patients with respiratory failure not caused by ARDS. 'Mechanical Power of ventilation' (MP), the amount of energy per time transferred from the ventilator to the respiratory system, is a summary variable that includes all the components that play a role in VILI. With fully-automated closed-loop ventilation, these components are no longer set by the operator, but under control of the algorithms in the ventilator.

Objective:

To compare MP under INTELLiVENT-adaptive support ventilation (ASV), a fully-automated closed-loop ventilation, with MP under conventional ventilation.

Hypothesis:

INTELLiVENT-ASV compared to conventional ventilation results in a lower MP.

Study design:

National, multicenter, crossover, randomized clinical trial.

Study population:

Invasively ventilated critically ill patients.

Methods:

The ventilator will be randomly switched between INTELLiVENT-ASV for 3 hours and conventional ventilation for 3 hours. The amount of MP is calculated using various equations proposed in the literature.

Study endpoints:

The primary endpoint is the amount of MP with each form of invasive ventilation.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Differences in burden and risks of the two ventilation strategies compared in the current study are not expected. Both modes of ventilation are interchangeably used as part of standard care in the participating centers. No other interventions are performed. Neither the collection of demographic and outcome data, nor the capturing of ventilation characteristics causes harm to patients.

Enrollment

96 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Admitted to one of the participating ICUs;
  • Receiving invasive ventilation through a standard endotracheal (i.e., oral) tube;
  • Expected to be ventilated > 24 hours; and
  • Ventilation is applied by a ventilator that can provide INTELLiVENT-ASV and conventional ventilation.

Exclusion criteria

  • Age under 18 years;
  • No written informed consent;
  • Morbidly obese; and
  • Any contra-indication for use of INTELLiVENT-ASV

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

96 participants in 2 patient groups

INTELLiVENT-ASV
Experimental group
Description:
Use of INTELLiVENT-ASV during 3 hours with 30 minutes wash-out time before.
Treatment:
Procedure: Procedure: INTELLiVENT-ASV
Conventional Ventilation
Active Comparator group
Description:
Use of conventional ventilation during 3 hours with 30 minutes wash-out time before.
Treatment:
Procedure: Procedure: Conventional ventilation

Trial documents
1

Trial contacts and locations

3

Loading...

Central trial contact

Laura A. Buiteman-Kruizinga, RN, BSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems